CMOS Biochip
Mature semiconductor manufacturing can support device-to-device consistency, scalable production, and lower long-term cost.
CMOS-AI smart electroporation
Sotai Biosystems
Building a semiconductor-enabled platform to make cell transfection and cell engineering more reproducible, less damaging, and easier to scale.
CMOS
Biochip architecture for manufacturable, repeatable cell-processing devices.
AI
Parameter optimization across pulse conditions, payloads, viability, and outcomes.
Cell Engineering
Designed for DNA, mRNA, siRNA, proteins, CRISPR/Cas, and primary-cell workflows.
Platform
From bulk electroporation to controllable cell-scale processing.
Sotai combines CMOS biochips, microelectrode arrays, pulse-control electronics, and biological readouts into a reproducible transfection feedback loop.
Microelectrode Arrays
Localized electric-field control enables more precise interaction among field strength, cell state, and payload delivery.
Smart Pulse Control
Standardized pulse delivery is designed to reduce operator variation and improve repeatability across experiments.
Low-Damage Workflow
The platform balances delivery efficiency with viability, recovery, expansion potential, and downstream cell function.
AI relevance
Structured biological process data for AI-driven optimization.
Sotai is designed to connect chip behavior, pulse parameters, cell response, payload type, transfection efficiency, viability, recovery, and functional outcomes.
- Cell type and payload-aware parameter search
- Efficiency, viability, and recovery as optimization objectives
- Experiment tracking for reproducible process development
- Future acceleration with GPU-enabled modeling and analytics
Regenerative Medicine Applications
Cell-engineering tools for regenerative medicine workflows.
Sotai is building a semiconductor-enabled platform for research and co-development involving stem cells, iPSCs, T/NK immune cells, and non-viral delivery.
Future cell pilots are expected to evaluate transfection efficiency, cell viability, viable-cell recovery, and batch-to-batch reproducibility.
Research status: These applications are future research and co-development directions. They do not indicate completed therapeutic, clinical, safety, or medical-device validation.
Stem Cells & iPSCs
Engineering workflows for gene delivery and viable-cell recovery.
T/NK Cell Engineering
Chip, interface, and data requirements for non-viral transfection or editing workflows.
Non-viral Delivery & Gene Editing
Process development for DNA, mRNA, proteins, and CRISPR/Cas payloads.
Hospitals & CRO/CDMO
Batch-to-batch reproducibility, closed-operation concepts, and process-data traceability.
Company
Taiwan-incorporated biomedical technology startup.
Sotai Biosystems is developing a CMOS-AI smart electroporation platform at the intersection of semiconductors, biological process control, and AI optimization.
Stage
Early platform validation
Financing need
USD 2M / NT$50-60M
Seeking
Strategic partners, AI infrastructure, CMOS ecosystem access
Contact
Build AI-driven cell engineering infrastructure with Sotai.
We welcome discussion with startup programs, strategic investors, semiconductor partners, healthcare AI teams, translational research groups, and biomanufacturing collaborators.
Executive Contacts
Dr. Bronte Sun
Chief Executive Officer
bronte@sotaibiosystems.com.tw
+886932308469
Dr. Chun-Lung Lien
Founder / Business Contact
andrew@sotaibiosystems.com.tw
+886-905-936-000